Citi downgraded Hims & Hers to Sell from Neutral with a $25 price target
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HIMS:
- Hims and Hers Health put volume heavy and directionally bearish
- Hims & Hers initiated with a Buy at BTIG
- Hims & Hers price target raised to $24 from $21 at Piper Sandler
- BofA says Hims’ semaglutide compounding opportunity may be shorter than expected
- End to tirzepatide shortage has read on Hims GLP-1 trajectory, says Leerink